NASDAQ:MGNX MacroGenics (MGNX) Stock Price, News & Analysis → Beta testers blew this thing up (From Prosper Trading Academy) (Ad) Free MGNX Stock Alerts $4.29 -0.18 (-4.03%) (As of 06/17/2024 ET) Add Compare Share Share Today's Range$4.23▼$4.4750-Day Range$3.31▼$18.5152-Week Range$3.14▼$21.88Volume1.63 million shsAverage Volume1.59 million shsMarket Capitalization$268.68 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get MacroGenics alerts: Email Address MacroGenics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside179.7% Upside$12.00 Price TargetShort InterestBearish16.95% of Float Sold ShortDividend StrengthN/ASustainability-1.61Upright™ Environmental ScoreNews Sentiment0.38Based on 6 Articles This WeekInsider TradingSelling Shares$799,192 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.04) to ($2.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.60 out of 5 starsMedical Sector66th out of 913 stocksPharmaceutical Preparations Industry24th out of 430 stocks 4.3 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageMacroGenics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about MacroGenics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.95% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MacroGenics has recently increased by 11.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for MacroGenics is -1.61. Previous Next 3.0 News and Social Media Coverage News SentimentMacroGenics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for MacroGenics this week, compared to 3 articles on an average week.Search Interest11 people have searched for MGNX on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows3 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $799,192.00 in company stock.Percentage Held by Insiders11.30% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MacroGenics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to grow in the coming year, from ($3.04) to ($2.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -11.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -11.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MacroGenics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading Academywhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About MacroGenics Stock (NASDAQ:MGNX)MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Read More MGNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGNX Stock News HeadlinesJune 13, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXJune 13, 2024 | globenewswire.comMacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study – Hagens BermanJune 11, 2024 | globenewswire.comMacroGenics to Participate in Upcoming Investor ConferenceJune 7, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 30, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 28, 2024 | stockhouse.comLost Money on MacroGenics, Inc.(MGNX)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationMay 27, 2024 | markets.businessinsider.comLevi & Korsinsky Reminds MacroGenics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - MGNXMay 25, 2024 | markets.businessinsider.comMGNX ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of MacroGenics, Inc. Shareholders Who Lost MoneyMay 25, 2024 | benzinga.comMacrogenics Stock (NASDAQ:MGNX), Analyst Ratings, Price Targets, PredictionsMay 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Millionaire-Makers: May EditionMay 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Iovance Biotherapeutics (IOVA)May 24, 2024 | markets.businessinsider.comDemystifying Macrogenics: Insights From 14 Analyst ReviewsMay 24, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: MacroGenics (MGNX) and Medtronic (MDT)May 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 17, 2024 | baystreet.caPancreatic Cancer Battle Intensifies with Biotech Sector's Advanced TreatmentsMay 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MacroGenics, Inc. - MGNXMay 14, 2024 | prnewswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against MacroGenics, Inc. and Encourages Investors to Contact the FirmMay 13, 2024 | markets.businessinsider.comHold Rating on MacroGenics Amid Safety and Efficacy Concerns for Vobra DuoMay 13, 2024 | tmcnet.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against MacroGenics, Inc. (MGNX)May 13, 2024 | globenewswire.comMacroGenics to Participate in Upcoming Investor ConferencesMay 13, 2024 | seekingalpha.comMacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)May 12, 2024 | finance.yahoo.comUS$15.10: That's What Analysts Think MacroGenics, Inc. (NASDAQ:MGNX) Is Worth After Its Latest ResultsMay 11, 2024 | wsj.comMacrogenics Inc.May 11, 2024 | msn.comBMO Capital Downgrades MacroGenics (MGNX)May 10, 2024 | msn.comMacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'See More Headlines Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/18/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MGNX CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees339Year Founded2000Price Target and Rating Average Stock Price Target$12.00 High Stock Price Target$25.00 Low Stock Price Target$4.00 Potential Upside/Downside+179.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,060,000.00 Net Margins-53.60% Pretax Margin-53.60% Return on Equity-98.01% Return on Assets-51.32% Debt Debt-to-Equity RatioN/A Current Ratio3.63 Quick Ratio3.61 Sales & Book Value Annual Sales$58.75 million Price / Sales4.57 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book1.74Miscellaneous Outstanding Shares62,630,000Free Float55,555,000Market Cap$268.68 million OptionableOptionable Beta2.02 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Scott Koenig M.D. (Age 72)Ph.D., President, CEO & Director Comp: $1.2MMr. James Karrels (Age 57)Senior VP, CFO & Corporate Secretary Comp: $693.31kDr. Stephen L. Eck M.D. (Age 69)Ph.D., Senior VP of Clinical Development & Chief Medical Officer Comp: $766.85kMr. Eric Blasius Risser (Age 51)Chief Operating Officer Comp: $651.36kDr. Thomas M. Spitznagel Ph.D. (Age 57)Senior Vice President of Technical Operations Comp: $550.97kDr. Ezio Bonvini M.D. (Age 70)Senior VP of Research & Chief Scientific Officer Comp: $612.21kMr. Jeffrey Stuart Peters (Age 53)Senior VP, General Counsel & Corporate Compliance Officer Ms. Lynn Cilinski (Age 66)VP, Controller & Treasurer More ExecutivesKey CompetitorsEpizymeNASDAQ:EPZMPuma BiotechnologyNASDAQ:PBYIRepare TherapeuticsNASDAQ:RPTXIntercept PharmaceuticalsNASDAQ:ICPTMirum PharmaceuticalsNASDAQ:MIRMView All CompetitorsInsiders & InstitutionsRA Capital Management L.P.Sold 1,971,056 shares on 5/17/2024Ownership: 3.324%Jacobs Levy Equity Management Inc.Bought 33,039 shares on 5/16/2024Ownership: 0.236%California State Teachers Retirement SystemBought 37,938 shares on 5/16/2024Ownership: 0.077%Janus Henderson Group PLCBought 33,403 shares on 5/16/2024Ownership: 0.053%Bellevue Group AGBought 12,549 shares on 5/15/2024Ownership: 15.912%View All Insider TransactionsView All Institutional Transactions MGNX Stock Analysis - Frequently Asked Questions Should I buy or sell MacroGenics stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MGNX shares. View MGNX analyst ratings or view top-rated stocks. What is MacroGenics' stock price target for 2024? 10 analysts have issued 12-month target prices for MacroGenics' stock. Their MGNX share price targets range from $4.00 to $25.00. On average, they predict the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 179.7% from the stock's current price. View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts. How have MGNX shares performed in 2024? MacroGenics' stock was trading at $9.62 on January 1st, 2024. Since then, MGNX shares have decreased by 55.4% and is now trading at $4.29. View the best growth stocks for 2024 here. When is MacroGenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our MGNX earnings forecast. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) released its earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by $0.17. The biopharmaceutical company had revenue of $9.10 million for the quarter, compared to analyst estimates of $13.63 million. MacroGenics had a negative trailing twelve-month return on equity of 98.01% and a negative net margin of 53.60%. What ETF holds MacroGenics' stock? iShares Genomics Immunology and Healthcare ETF holds 100,383 shares of MGNX stock, representing 0.32% of its portfolio. What is Scott Koenig's approval rating as MacroGenics' CEO? 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC). Who are MacroGenics' major shareholders? MacroGenics' stock is owned by a number of institutional and retail investors. Top institutional investors include Bellevue Group AG (15.91%), Avoro Capital Advisors LLC (9.82%), Vanguard Group Inc. (5.88%), Price T Rowe Associates Inc. MD (3.89%), RA Capital Management L.P. (3.32%) and Wasatch Advisors LP (1.58%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGNX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.